graft-versus-host disease

[Blood Advances] To optimize the selection of stem cell transplant sources based on the HLA-B leader, an HLA-B Leader Assessment Tool was developed to automate the assignment of leader genotypes, define HLA-B leader match statuses, and rank order candidate stem cell sources according to clinical risk.

[Bone Marrow Transplantation] Investigators analyzed 144 acute leukemia haploidentical hematopoietic-cell transplantation using post-transplant cyclophosphamide pediatric recipients; median age was ten years.

[Frontiers in Immunology] Scientists described an anti-HLA-A2 CAR generated by grafting the complementarity-determining regions of a human monoclonal anti-HLA-A2 antibody into the framework regions of the Herceptin 4D5 single-chain variable fragment and fusing it with a CD28-ζ signaling domain.

[International Immunopharmacology] To better understand the role of MSC in the prevention and treatment of graft-versus-host disease, umbilical cord derived MSCs were pre-treated with Chinese medicine Asarinin and IFN-γ.

[Blood Advances] The pathophysiology of poor graft function can be conceptualized as dysfunction related to the number or productivity of the stem cell compartment, defects in bone marrow microenvironment components such as mesenchymal stromal cells and endothelial cells, or immunological suppression of post allogeneic stem cell transplant hematopoiesis.

[Bone Marrow Transplantation] Investigators conducted a single-center Phase I dose-escalation study with lenalidomide maintenance in high-risk myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic transplantation.